PMC:7172841 / 6891-9350 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T33","span":{"begin":829,"end":845},"obj":"Body_part"},{"id":"T34","span":{"begin":841,"end":845},"obj":"Body_part"},{"id":"T35","span":{"begin":958,"end":966},"obj":"Body_part"},{"id":"T36","span":{"begin":1810,"end":1815},"obj":"Body_part"},{"id":"T37","span":{"begin":1885,"end":1890},"obj":"Body_part"},{"id":"T38","span":{"begin":2131,"end":2138},"obj":"Body_part"},{"id":"T39","span":{"begin":2435,"end":2440},"obj":"Body_part"}],"attributes":[{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma62852"},{"id":"A34","pred":"fma_id","subj":"T34","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A35","pred":"fma_id","subj":"T35","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A36","pred":"fma_id","subj":"T36","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A37","pred":"fma_id","subj":"T37","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A38","pred":"fma_id","subj":"T38","obj":"http://purl.org/sig/ont/fma/fma82749"},{"id":"A39","pred":"fma_id","subj":"T39","obj":"http://purl.org/sig/ont/fma/fma67498"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":835,"end":840},"obj":"Body_part"},{"id":"T7","span":{"begin":1810,"end":1815},"obj":"Body_part"},{"id":"T8","span":{"begin":1885,"end":1890},"obj":"Body_part"},{"id":"T9","span":{"begin":2435,"end":2440},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T75","span":{"begin":96,"end":105},"obj":"Disease"},{"id":"T76","span":{"begin":116,"end":124},"obj":"Disease"},{"id":"T77","span":{"begin":116,"end":120},"obj":"Disease"},{"id":"T78","span":{"begin":130,"end":149},"obj":"Disease"},{"id":"T79","span":{"begin":157,"end":176},"obj":"Disease"},{"id":"T80","span":{"begin":187,"end":195},"obj":"Disease"},{"id":"T81","span":{"begin":187,"end":191},"obj":"Disease"},{"id":"T82","span":{"begin":216,"end":224},"obj":"Disease"},{"id":"T83","span":{"begin":216,"end":220},"obj":"Disease"},{"id":"T84","span":{"begin":1724,"end":1748},"obj":"Disease"},{"id":"T85","span":{"begin":1731,"end":1748},"obj":"Disease"},{"id":"T86","span":{"begin":1810,"end":1823},"obj":"Disease"},{"id":"T87","span":{"begin":1876,"end":1898},"obj":"Disease"},{"id":"T88","span":{"begin":1885,"end":1898},"obj":"Disease"},{"id":"T89","span":{"begin":1993,"end":2012},"obj":"Disease"},{"id":"T90","span":{"begin":2368,"end":2377},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"},{"id":"A76","pred":"mondo_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A77","pred":"mondo_id","subj":"T77","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A78","pred":"mondo_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A79","pred":"mondo_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005252"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005010"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005267"},{"id":"A89","pred":"mondo_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T41","span":{"begin":254,"end":256},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T42","span":{"begin":355,"end":359},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T43","span":{"begin":355,"end":359},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T44","span":{"begin":400,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T45","span":{"begin":835,"end":840},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T46","span":{"begin":841,"end":845},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T47","span":{"begin":1810,"end":1815},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T48","span":{"begin":1810,"end":1815},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T49","span":{"begin":1810,"end":1815},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T50","span":{"begin":1810,"end":1815},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T51","span":{"begin":1848,"end":1850},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T52","span":{"begin":1885,"end":1890},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T53","span":{"begin":1885,"end":1890},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T54","span":{"begin":1885,"end":1890},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T55","span":{"begin":1885,"end":1890},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T56","span":{"begin":2032,"end":2036},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T57","span":{"begin":2163,"end":2172},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T58","span":{"begin":2435,"end":2440},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T28","span":{"begin":285,"end":287},"obj":"Chemical"},{"id":"T29","span":{"begin":437,"end":439},"obj":"Chemical"},{"id":"T30","span":{"begin":454,"end":456},"obj":"Chemical"},{"id":"T31","span":{"begin":548,"end":550},"obj":"Chemical"},{"id":"T32","span":{"begin":633,"end":635},"obj":"Chemical"},{"id":"T33","span":{"begin":716,"end":718},"obj":"Chemical"},{"id":"T34","span":{"begin":818,"end":820},"obj":"Chemical"},{"id":"T35","span":{"begin":1375,"end":1385},"obj":"Chemical"},{"id":"T36","span":{"begin":1463,"end":1472},"obj":"Chemical"},{"id":"T37","span":{"begin":1544,"end":1547},"obj":"Chemical"},{"id":"T38","span":{"begin":2131,"end":2138},"obj":"Chemical"},{"id":"T39","span":{"begin":2202,"end":2205},"obj":"Chemical"},{"id":"T40","span":{"begin":2207,"end":2216},"obj":"Chemical"},{"id":"T43","span":{"begin":2394,"end":2396},"obj":"Chemical"}],"attributes":[{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_16737"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_16449"},{"id":"A39","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_132943"},{"id":"A41","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_29995"},{"id":"A42","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_72314"},{"id":"A43","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_74807"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-sentences","denotations":[{"id":"T49","span":{"begin":0,"end":126},"obj":"Sentence"},{"id":"T50","span":{"begin":127,"end":176},"obj":"Sentence"},{"id":"T51","span":{"begin":177,"end":234},"obj":"Sentence"},{"id":"T52","span":{"begin":235,"end":265},"obj":"Sentence"},{"id":"T53","span":{"begin":266,"end":354},"obj":"Sentence"},{"id":"T54","span":{"begin":355,"end":429},"obj":"Sentence"},{"id":"T55","span":{"begin":430,"end":528},"obj":"Sentence"},{"id":"T56","span":{"begin":529,"end":620},"obj":"Sentence"},{"id":"T57","span":{"begin":621,"end":703},"obj":"Sentence"},{"id":"T58","span":{"begin":704,"end":791},"obj":"Sentence"},{"id":"T59","span":{"begin":792,"end":821},"obj":"Sentence"},{"id":"T60","span":{"begin":822,"end":947},"obj":"Sentence"},{"id":"T61","span":{"begin":948,"end":1053},"obj":"Sentence"},{"id":"T62","span":{"begin":1054,"end":1120},"obj":"Sentence"},{"id":"T63","span":{"begin":1121,"end":1201},"obj":"Sentence"},{"id":"T64","span":{"begin":1202,"end":1291},"obj":"Sentence"},{"id":"T65","span":{"begin":1292,"end":1373},"obj":"Sentence"},{"id":"T66","span":{"begin":1374,"end":1455},"obj":"Sentence"},{"id":"T67","span":{"begin":1456,"end":1542},"obj":"Sentence"},{"id":"T68","span":{"begin":1543,"end":1619},"obj":"Sentence"},{"id":"T69","span":{"begin":1620,"end":1696},"obj":"Sentence"},{"id":"T70","span":{"begin":1697,"end":1722},"obj":"Sentence"},{"id":"T71","span":{"begin":1723,"end":1800},"obj":"Sentence"},{"id":"T72","span":{"begin":1801,"end":1874},"obj":"Sentence"},{"id":"T73","span":{"begin":1875,"end":1945},"obj":"Sentence"},{"id":"T74","span":{"begin":1946,"end":2095},"obj":"Sentence"},{"id":"T75","span":{"begin":2096,"end":2459},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":96,"end":105},"obj":"Phenotype"},{"id":"T36","span":{"begin":130,"end":149},"obj":"Phenotype"},{"id":"T37","span":{"begin":157,"end":176},"obj":"Phenotype"},{"id":"T38","span":{"begin":1724,"end":1739},"obj":"Phenotype"},{"id":"T39","span":{"begin":1802,"end":1823},"obj":"Phenotype"},{"id":"T40","span":{"begin":1993,"end":2012},"obj":"Phenotype"},{"id":"T41","span":{"begin":2368,"end":2377},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A38","pred":"hp_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/HP_0005978"},{"id":"A39","pred":"hp_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/HP_0001635"},{"id":"A40","pred":"hp_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A41","pred":"hp_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T162","span":{"begin":116,"end":126},"obj":"SP_7"},{"id":"T163","span":{"begin":1993,"end":2004},"obj":"UBERON:0001004"},{"id":"T164","span":{"begin":2435,"end":2440},"obj":"UBERON:0000062"},{"id":"T63","span":{"begin":157,"end":168},"obj":"UBERON:0001004"},{"id":"T270","span":{"begin":14,"end":17},"obj":"PR:000029150"},{"id":"T271","span":{"begin":24,"end":28},"obj":"PR:000001889"},{"id":"T272","span":{"begin":29,"end":38},"obj":"CL:0000576"},{"id":"T273","span":{"begin":96,"end":106},"obj":"SP_7"},{"id":"T274","span":{"begin":147,"end":152},"obj":"UBERON:0002405;GO:0006955"},{"id":"T275","span":{"begin":153,"end":164},"obj":"GO:0006955"},{"id":"T276","span":{"begin":170,"end":178},"obj":"CHEBI:82594;CHEBI:82594"},{"id":"T277","span":{"begin":201,"end":206},"obj":"UBERON:0001977"},{"id":"T278","span":{"begin":224,"end":233},"obj":"NCBITaxon:2"},{"id":"T279","span":{"begin":326,"end":342},"obj":"GO:0006909"},{"id":"T280","span":{"begin":383,"end":393},"obj":"SP_7"},{"id":"T281","span":{"begin":433,"end":438},"obj":"UBERON:0002405;GO:0006955"},{"id":"T282","span":{"begin":439,"end":449},"obj":"GO:0006955"},{"id":"T283","span":{"begin":464,"end":472},"obj":"CL:0000775"},{"id":"T284","span":{"begin":514,"end":524},"obj":"SP_7"},{"id":"T285","span":{"begin":564,"end":569},"obj":"UBERON:0002405;GO:0006955"},{"id":"T286","span":{"begin":570,"end":580},"obj":"GO:0006955"},{"id":"T287","span":{"begin":595,"end":603},"obj":"CL:0000576"},{"id":"T95576","span":{"begin":645,"end":655},"obj":"SP_7"},{"id":"T289","span":{"begin":695,"end":700},"obj":"UBERON:0002405;GO:0006955"},{"id":"T290","span":{"begin":701,"end":711},"obj":"GO:0006955"},{"id":"T17416","span":{"begin":1070,"end":1080},"obj":"SP_7"},{"id":"T36679","span":{"begin":1108,"end":1111},"obj":"PR:000001004"},{"id":"T46992","span":{"begin":1112,"end":1116},"obj":"PR:000001006"},{"id":"T27901","span":{"begin":1118,"end":1130},"obj":"CL:0000542"},{"id":"T61002","span":{"begin":1140,"end":1144},"obj":"PR:000001006"},{"id":"T78906","span":{"begin":1146,"end":1157},"obj":"CL:0000542"},{"id":"T18777","span":{"begin":1163,"end":1167},"obj":"PR:000001483"},{"id":"T82514","span":{"begin":1168,"end":1172},"obj":"PR:000001024"},{"id":"T67194","span":{"begin":1173,"end":1177},"obj":"PR:000001006"},{"id":"T57852","span":{"begin":1190,"end":1194},"obj":"PR:000001002"},{"id":"T74187","span":{"begin":1195,"end":1199},"obj":"PR:000001006"},{"id":"T51485","span":{"begin":1201,"end":1213},"obj":"CL:0000542"},{"id":"T75127","span":{"begin":1245,"end":1253},"obj":"SP_7"},{"id":"T79014","span":{"begin":1394,"end":1402},"obj":"SP_7"},{"id":"T84083","span":{"begin":1417,"end":1420},"obj":"PR:000001004"},{"id":"T30397","span":{"begin":1421,"end":1425},"obj":"PR:000001006"},{"id":"T75758","span":{"begin":1427,"end":1438},"obj":"CL:0000542"},{"id":"T41299","span":{"begin":1454,"end":1459},"obj":"PR:000001483"},{"id":"T12888","span":{"begin":1460,"end":1464},"obj":"PR:000001006"},{"id":"T4856","span":{"begin":1476,"end":1480},"obj":"PR:000001002"},{"id":"T26978","span":{"begin":1481,"end":1485},"obj":"PR:000001006"},{"id":"T99843","span":{"begin":1487,"end":1498},"obj":"CL:0000542"},{"id":"T26411","span":{"begin":1536,"end":1541},"obj":"UBERON:0002405"},{"id":"T52616","span":{"begin":1542,"end":1556},"obj":"GO:0065007"},{"id":"T19523","span":{"begin":1567,"end":1575},"obj":"SP_7"},{"id":"T71646","span":{"begin":1601,"end":1604},"obj":"PR:000001004"},{"id":"T34262","span":{"begin":1606,"end":1610},"obj":"PR:000001006"},{"id":"T24520","span":{"begin":1612,"end":1624},"obj":"CL:0000542"},{"id":"T18346","span":{"begin":1634,"end":1638},"obj":"PR:000001006"},{"id":"T91659","span":{"begin":1640,"end":1651},"obj":"CL:0000542"},{"id":"T48046","span":{"begin":1661,"end":1665},"obj":"PR:000001483"},{"id":"T24770","span":{"begin":1666,"end":1670},"obj":"PR:000001024"},{"id":"T13763","span":{"begin":1671,"end":1675},"obj":"PR:000001006"},{"id":"T41969","span":{"begin":1713,"end":1718},"obj":"UBERON:0002405"},{"id":"T34348","span":{"begin":1811,"end":1818},"obj":"NCBITaxon:10239"},{"id":"T64438","span":{"begin":1851,"end":1861},"obj":"SP_7"},{"id":"T57025","span":{"begin":1892,"end":1895},"obj":"PR:000001004"},{"id":"T64196","span":{"begin":1896,"end":1900},"obj":"PR:000001006"},{"id":"T43300","span":{"begin":1902,"end":1913},"obj":"CL:0000542"},{"id":"T63493","span":{"begin":1934,"end":1938},"obj":"PR:000001483"},{"id":"T53839","span":{"begin":1939,"end":1943},"obj":"PR:000001024"},{"id":"T83790","span":{"begin":1944,"end":1948},"obj":"PR:000001006"},{"id":"T90081","span":{"begin":1960,"end":1964},"obj":"PR:000001002"},{"id":"T61628","span":{"begin":1965,"end":1969},"obj":"PR:000001006"},{"id":"T45644","span":{"begin":1971,"end":1982},"obj":"CL:0000542"},{"id":"T49355","span":{"begin":2048,"end":2053},"obj":"PR:000001092;GO:0032620"},{"id":"T76356","span":{"begin":2054,"end":2064},"obj":"GO:0032620"},{"id":"T18711","span":{"begin":2112,"end":2117},"obj":"UBERON:0002405"},{"id":"T74798","span":{"begin":2118,"end":2131},"obj":"GO:0065007"},{"id":"T65161","span":{"begin":2220,"end":2230},"obj":"SP_7"},{"id":"T20688","span":{"begin":2259,"end":2262},"obj":"PR:000001004"},{"id":"T1928","span":{"begin":2263,"end":2267},"obj":"PR:000001006"},{"id":"T55211","span":{"begin":2269,"end":2280},"obj":"CL:0000542"},{"id":"T81656","span":{"begin":2294,"end":2298},"obj":"PR:000001006"},{"id":"T87232","span":{"begin":2300,"end":2311},"obj":"CL:0000542"},{"id":"T85579","span":{"begin":2321,"end":2325},"obj":"PR:000001483"},{"id":"T21243","span":{"begin":2326,"end":2330},"obj":"PR:000001024"},{"id":"T53498","span":{"begin":2331,"end":2335},"obj":"PR:000001006"},{"id":"T56782","span":{"begin":2337,"end":2348},"obj":"CL:0000542"},{"id":"T84027","span":{"begin":2358,"end":2362},"obj":"PR:000001483"},{"id":"T83216","span":{"begin":2363,"end":2367},"obj":"PR:000001024"},{"id":"T41056","span":{"begin":2368,"end":2372},"obj":"PR:000001006"},{"id":"T91153","span":{"begin":2389,"end":2393},"obj":"PR:000001002"},{"id":"T83343","span":{"begin":2394,"end":2398},"obj":"PR:000001006"},{"id":"T84418","span":{"begin":2400,"end":2411},"obj":"CL:0000542"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}

{"project":"LitCovid-PubTator","denotations":[{"id":"222","span":{"begin":1544,"end":1547},"obj":"Gene"},{"id":"223","span":{"begin":187,"end":197},"obj":"Species"},{"id":"224","span":{"begin":216,"end":226},"obj":"Species"},{"id":"225","span":{"begin":245,"end":253},"obj":"Species"},{"id":"226","span":{"begin":1375,"end":1385},"obj":"Chemical"},{"id":"227","span":{"begin":130,"end":149},"obj":"Disease"},{"id":"228","span":{"begin":157,"end":176},"obj":"Disease"},{"id":"229","span":{"begin":1731,"end":1748},"obj":"Disease"},{"id":"230","span":{"begin":1802,"end":1823},"obj":"Disease"},{"id":"231","span":{"begin":1876,"end":1898},"obj":"Disease"},{"id":"233","span":{"begin":96,"end":105},"obj":"Disease"},{"id":"239","span":{"begin":2131,"end":2155},"obj":"Gene"},{"id":"240","span":{"begin":2202,"end":2205},"obj":"Gene"},{"id":"241","span":{"begin":1993,"end":2012},"obj":"Disease"},{"id":"242","span":{"begin":2368,"end":2377},"obj":"Disease"},{"id":"243","span":{"begin":2435,"end":2448},"obj":"Disease"}],"attributes":[{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"Gene:26503"},{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"Tax:2697049"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"Tax:2697049"},{"id":"A225","pred":"tao:has_database_id","subj":"225","obj":"Tax:9606"},{"id":"A226","pred":"tao:has_database_id","subj":"226","obj":"MESH:D003404"},{"id":"A227","pred":"tao:has_database_id","subj":"227","obj":"MESH:D012131"},{"id":"A228","pred":"tao:has_database_id","subj":"228","obj":"MESH:D012131"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"MESH:D003920"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"MESH:D006333"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"MESH:D003324"},{"id":"A233","pred":"tao:has_database_id","subj":"233","obj":"MESH:D011014"},{"id":"A239","pred":"tao:has_database_id","subj":"239","obj":"Gene:2875"},{"id":"A240","pred":"tao:has_database_id","subj":"240","obj":"Gene:26503"},{"id":"A241","pred":"tao:has_database_id","subj":"241","obj":"MESH:D012131"},{"id":"A242","pred":"tao:has_database_id","subj":"242","obj":"MESH:D011014"},{"id":"A243","pred":"tao:has_database_id","subj":"243","obj":"MESH:D009102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 1 Baseline Clinical and Laboratory Characteristics of the Cohorts of Bacterial CAP and of Pneumonia Caused by SARS-CoV-2\nNo respiratory failure Severe respiratory failure\nBacterial SARS-CoV-2 p value Bacterial SARS-CoV-2 p value\nNumber of patients 48 26 56 28\nAge (years, mean ± SD) 74.8 ± 16.8 59.2 ± 10.3 \u003c0.0001 74.0 ± 12.6∗ 67.8 ± 10.8# \u003c0.0001\nMale gender (n, %) 25 (52.1) 15 (57.7) 0.807 27 (48.2)∗ 25 (89.3)∗∗ 0.0003\nAPACHE II score (mean ± SD) 18.50 ± 8.19 5.88 ± 3.40 \u003c0.0001 26.63 ± 8.52∗∗ 10.17 ± 3.64## \u003c0.0001\nSOFA score (mean ± SD) 7.87 ± 3.81 1.50 ± 0.82 \u003c0.0001 11.46 ± 3.15∗∗ 5.71 ± 2.19## \u003c0.0001\nCCI (mean ± SD) 5.53 ± 2.13 2.16 ± 1.46 \u003c0.0001 5.57 ± 2.20∗ 3.39 ± 2.16## \u003c0.0001\nPSI (mean ± SD) 146.5 ± 43.2 80.0 ± 30.7 \u003c0.0001 177.4 ± 40.4∗∗∗ 121.2 ± 28.3## \u003c0.0001\nLaboratory values (mean ± SD)\n Total white blood cell count (/mm3) 13,852.7 ± 7279.3 6379.6 ± 1993.9 \u003c0.0001 17,666.9 ± 12,799.9∗ 9447.8 ± 3308.6## \u003c0.0001\n Absolute platelet count (x103 /mm3) 201.3 ± 124.8 243.8 ± 109.1 0.141 224.3 ± 111.0∗ 213.9 ± 71.8∗ 0.654\n INR 1.28 ± 0.64 1.11 ± 0.15 0.187 1.33 ± 0.45∗ 1.17 ± 0.20∗ 0.077\n aPTT (secs) 37.19 ± 12.95 33.40 ± 6.22 0.165 38.42 ± 23.00∗ 37.52 ± 9.88∗ 0.844\n Fibrinogen (mg/dl) 475.6 ± 196.3 528.9 ± 152.5 0.234 495.3 ± 290.5∗ 693.5 ± 188.6# 0.002\n D-dimers (g/dl) 7.66 ± 13.9 2.76 ± 2.02 0.079 1.46 ± 1.62∗∗ 5.43 ± 6.41∗ \u003c0.0001\n Creatinine (mg/dl) 1.55 ± 1.00 0.85 ± 0.19 0.001 1.71 ± 0.90∗ 1.11 ± 0.43# 0.001\n Total bilirubin (mg/dl) 1.43 ± 1.92 0.67 ± 0.50 0.052 1.17 ± 1.88∗ 0.97 ± 0.68∗ 0.588\n AST (U/l) 155.1 ± 308.1 39.9 ± 28.5 0.062 311.7 ± 748.2∗ 76.6 ± 59.2# 0.102\n ALT (U/l) 234.6 ± 764.3 40.2 ± 24.9 0.200 175.8 ± 378.0∗ 64.3 ± 62.2∗ 0.126\nMain comorbidities (n, %)\n Type 2 diabetes mellitus 13 (27.1) 4 (15.4) 0.386 21 (37.5)∗ 6 (21.4)∗ 0.214\n Chronic heart failure 8 (16.7) 3 (11.5) 0.737 18 (32.1)∗ 4 (14.3)∗ 0.114\n Coronary heart disease 7 (14.6) 2 (7.7) 0.479 10 (17.9) 5 (17.9)∗ 1.0\nComparisons with the respective groups without respiratory failure by the Student’s t test: ∗p-non-significant; ∗∗p \u003c 0.05; #p \u003c 0.001; ##p \u003c 0.0001. Abbreviations are as follows: ALT, alanine aminotransferase; aPTT, activated partial thromboplastin time; AST, aspartate aminotransferase; APACHE, acute physiology and chronic health evaluation; CCI, Charlson’s comorbidity index; INR, international normalized ratio; PSI, pneumonia severity index; SD, standard deviation; SOFA, sequential organ failure assessment"}